ATE286121T1 - Protein-c-derivat - Google Patents

Protein-c-derivat

Info

Publication number
ATE286121T1
ATE286121T1 AT93303894T AT93303894T ATE286121T1 AT E286121 T1 ATE286121 T1 AT E286121T1 AT 93303894 T AT93303894 T AT 93303894T AT 93303894 T AT93303894 T AT 93303894T AT E286121 T1 ATE286121 T1 AT E286121T1
Authority
AT
Austria
Prior art keywords
derivatives
human protein
protein
derivative
producing
Prior art date
Application number
AT93303894T
Other languages
English (en)
Inventor
Bruce Edward Gerlitz
Brian William Grinnell
Original Assignee
Lilly Co Eli
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lilly Co Eli filed Critical Lilly Co Eli
Application granted granted Critical
Publication of ATE286121T1 publication Critical patent/ATE286121T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/745—Blood coagulation or fibrinolysis factors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
    • C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
    • C12N9/64—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue
    • C12N9/6421—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue from mammals
    • C12N9/6424—Serine endopeptidases (3.4.21)
    • C12N9/6464—Protein C (3.4.21.69)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y304/00—Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
    • C12Y304/21—Serine endopeptidases (3.4.21)
    • C12Y304/21069—Protein C activated (3.4.21.69)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Zoology (AREA)
  • General Health & Medical Sciences (AREA)
  • Wood Science & Technology (AREA)
  • Biochemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Biomedical Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Hematology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Diabetes (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Toxicology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
AT93303894T 1992-05-21 1993-05-19 Protein-c-derivat ATE286121T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US88719192A 1992-05-21 1992-05-21

Publications (1)

Publication Number Publication Date
ATE286121T1 true ATE286121T1 (de) 2005-01-15

Family

ID=25390640

Family Applications (1)

Application Number Title Priority Date Filing Date
AT93303894T ATE286121T1 (de) 1992-05-21 1993-05-19 Protein-c-derivat

Country Status (23)

Country Link
US (1) US5453373A (de)
EP (1) EP0575054B1 (de)
JP (1) JP3564150B2 (de)
KR (1) KR100291529B1 (de)
CN (1) CN1080658A (de)
AT (1) ATE286121T1 (de)
AU (1) AU661901B2 (de)
BR (1) BR9301944A (de)
CA (1) CA2096604C (de)
CZ (1) CZ286016B6 (de)
DE (1) DE69333727T2 (de)
DK (1) DK0575054T3 (de)
ES (1) ES2233925T3 (de)
FI (1) FI932282L (de)
HU (1) HU218408B (de)
IL (1) IL105757A0 (de)
MX (1) MX9302917A (de)
MY (1) MY110664A (de)
NO (1) NO311299B1 (de)
NZ (1) NZ247651A (de)
PH (1) PH29911A (de)
PT (1) PT575054E (de)
RU (1) RU2122004C1 (de)

Families Citing this family (39)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2067525C (en) * 1991-05-09 1998-09-15 Helmut G. Alt Organometallic fluorenyl compounds, preparation and use
AT402262B (de) * 1991-06-20 1997-03-25 Immuno Ag Arzneimittel enthaltend aktiviertes protein c
US5716795A (en) * 1991-10-04 1998-02-10 Matschiner; John T. Thrombomodulin-based coagulometric assay of the protein C system
AU2870992A (en) * 1991-10-04 1993-05-03 Board Of Regents Of The University Of Nebraska, The A soluble thrombomodulin-based one-stage assay for vitamin k-dependent coagulation-inhibiting proteins
DE4320294A1 (de) * 1993-06-18 1994-12-22 Immuno Ag Verwendung von humanem Protein C zur Verhinderung und Behandlung von Thrombozytenablagerungen
US6630137B1 (en) 1997-04-28 2003-10-07 Eli Lilly And Company Activated protein C formulations
CZ298429B6 (cs) 1997-04-28 2007-10-03 Eli Lilly And Company Stabilní lyofilizovaný prostredek
WO1998055142A1 (en) * 1997-06-05 1998-12-10 Eli Lilly And Company Methods for treating thrombotic disorders
HUP0001237A3 (en) * 1997-10-20 2002-01-28 Lilly Co Eli Methods for treating vascular disorders
US6815533B1 (en) 1998-07-31 2004-11-09 Eli Lilly And Company Cryogranulation of activated protein C
CA2338766A1 (en) * 1998-07-31 2000-02-10 Eli Lilly And Company Cryogranulation of activated protein c
CN1324244A (zh) 1998-10-22 2001-11-28 伊莱利利公司 治疗脓毒症的方法
CN1326355A (zh) 1998-11-13 2001-12-12 伊莱利利公司 治疗肝素诱导的血小板减少症的方法
CA2351470A1 (en) 1998-11-20 2000-06-02 Charles Jack Fisher Method of treating viral hemorrhagic fever
ATE232739T1 (de) 1998-11-23 2003-03-15 Lilly Co Eli Protein c zur behandlung von sichelzellanämie und thalassämie
US6998122B1 (en) * 1999-04-30 2006-02-14 Eli Lilly And Company Protein C derivatives
WO2001036462A2 (en) * 1999-11-19 2001-05-25 Eli Lilly And Company Protein c derivatives
WO2001057193A2 (en) * 2000-02-02 2001-08-09 Eli Lilly And Company Protein c derivatives
CA2400187A1 (en) * 2000-02-11 2001-08-16 Eli Lilly And Company Protein c derivatives
US7204981B2 (en) * 2000-03-28 2007-04-17 Eli Lilly And Company Methods of treating diseases with activated protein C
WO2002032461A2 (en) * 2000-10-18 2002-04-25 Maxygen Aps Protein c or activated protein c-like molecules
BR0114771A (pt) * 2000-10-18 2004-07-27 Maxygen Aps Moléculas de proteìna c ou semelhantes a proteìna c ativada
US6933367B2 (en) 2000-10-18 2005-08-23 Maxygen Aps Protein C or activated protein C-like molecules
US20040198652A1 (en) * 2001-04-24 2004-10-07 Carter J. Paul Methods and compositions for preventing and treating septic shock and endotoxemia
EP1485121A4 (de) * 2002-03-08 2007-11-07 Lilly Co Eli Aktivierte protein-c-formulierungen
AU2003232176A1 (en) * 2002-06-14 2003-12-31 Maxygen Aps Protein c variants with altered properties
US20070142272A1 (en) * 2003-01-24 2007-06-21 Zlokovic Berislav V Neuroprotective activity of activated protein c independent of its anticoagulant activity
JP2008507561A (ja) * 2004-07-23 2008-03-13 ザ ユニバーシティ オブ ロチェスター 活性化プロテインｃによる、脳内のプラスミノゲン活性化因子の不都合な作用の阻害
CN101198696B (zh) * 2005-04-13 2014-02-26 阿斯利康(瑞典)有限公司 包含产生需要γ-羧化的蛋白质用的载体的宿主细胞
US20090148458A1 (en) * 2005-06-23 2009-06-11 The University Of British Columbia Coagulation factor iii polymorphisms associated with prediction of subject outcome and response to therapy
CA2654761A1 (en) * 2006-06-09 2007-12-13 The University Of British Columbia Interferon gamma polymorphisms as indicators of subject outcome in critically ill subjects
ATE520414T1 (de) * 2007-06-18 2011-09-15 Univ Oregon Health & Science Protein c zur verwendung bei der aufrechterhaltung der hämostase
US20110171200A1 (en) * 2008-01-15 2011-07-14 Walley Keith R Protein c rs2069915 as a response predictor to survival and administration of activated protein c or protein c-like compound
JP5833448B2 (ja) 2008-12-19 2015-12-16 アンスティチュ ナショナル ドゥ ラ サンテ エ ドゥ ラ ルシェルシュ メディカル セリンプロテアーゼ誘導体および血液凝固疾患の予防または処置における使用
WO2012068519A2 (en) 2010-11-19 2012-05-24 Sirius Genomics Inc. Markers associated with response to activated protein c administration, and uses thereof
JP6273272B2 (ja) 2012-07-04 2018-01-31 ジージー バイオテック エルエルシー 炎症性皮膚障害の治療
JP2017513944A (ja) 2014-04-16 2017-06-01 ジージー バイオテック エルエルシー 異常な皮膚瘢痕化の治療
CA2946032C (en) 2014-04-16 2022-06-14 Zz Biotech Llc Use of apc analogue for wound healing
WO2023119230A1 (en) 2021-12-22 2023-06-29 L'oreal Coagulation pathway and nicotinamide-adenine dinucleotide pathway modulating compositions and methods of their use

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SU1637807A1 (ru) * 1984-04-10 1991-03-30 Полтавский медицинский стоматологический институт Средство дл индивидуальной профилактики венерических заболеваний у мужчин
US4775624A (en) * 1985-02-08 1988-10-04 Eli Lilly And Company Vectors and compounds for expression of human protein C
US4992373A (en) * 1987-12-04 1991-02-12 Eli Lilly And Company Vectors and compounds for direct expression of activated human protein C
ZA889497B (en) * 1987-12-28 1990-08-29 Lilly Co Eli Vectors and compounds for expression of zymogen forms of human protein c
US4981952A (en) * 1988-10-04 1991-01-01 Eli Lilly And Company Method for the purification of vitamin K-dependent proteins
US5270178A (en) * 1990-02-23 1993-12-14 Eli Lilly And Company Vectors and compounds for expression of zymogen forms of human protein C
IL97311A0 (en) * 1990-02-23 1992-05-25 Lilly Co Eli Vectors and compounds for expression of glycosylation mutants of human protein c

Also Published As

Publication number Publication date
PT575054E (pt) 2005-03-31
PH29911A (en) 1996-09-16
JPH0680698A (ja) 1994-03-22
NO931840L (no) 1993-11-22
HU218408B (hu) 2000-08-28
IL105757A0 (en) 1993-09-22
HU9301461D0 (en) 1993-09-28
CA2096604C (en) 2003-12-16
NZ247651A (en) 1995-03-28
CZ286016B6 (cs) 1999-12-15
NO931840D0 (no) 1993-05-19
FI932282A7 (fi) 1993-11-22
CA2096604A1 (en) 1993-11-22
MX9302917A (es) 1993-11-01
ES2233925T3 (es) 2005-06-16
HUT69615A (en) 1995-09-28
RU2122004C1 (ru) 1998-11-20
BR9301944A (pt) 1993-11-30
DE69333727D1 (de) 2005-02-03
NO311299B1 (no) 2001-11-12
EP0575054A3 (de) 1995-04-19
KR930023370A (ko) 1993-12-18
KR100291529B1 (ko) 2001-06-01
FI932282L (fi) 1993-11-22
US5453373A (en) 1995-09-26
AU661901B2 (en) 1995-08-10
AU3869993A (en) 1993-11-25
CZ94893A3 (en) 1994-01-19
EP0575054A2 (de) 1993-12-22
EP0575054B1 (de) 2004-12-29
DE69333727T2 (de) 2005-12-15
JP3564150B2 (ja) 2004-09-08
MY110664A (en) 1999-01-30
DK0575054T3 (da) 2005-04-25
FI932282A0 (fi) 1993-05-19
CN1080658A (zh) 1994-01-12

Similar Documents

Publication Publication Date Title
ATE286121T1 (de) Protein-c-derivat
NO900770L (no) Produksjon av glykoseoksidase i rekombinante systemer.
ATE188486T1 (de) Modifizierte polypeptide mit erhoehter biologischer aktivitaet
DK172089D0 (da) 1,3-dioxolanderivater samt fremgangsmaade til fremstilling deraf
ATE133181T1 (de) Dehydrodidemnin b
RU93005089A (ru) Производное белка с человека, днк, клетка, фармацевтическая композиция, применение производного белка с, способ получения
DK0960127T3 (da) Isoleret dimert fibroblastaktiverende protein-alfa og anvendelser deraf
NO910719D0 (no) Vektorer og forbindelser for ekspresjon av glykosyleringsmutanter av humant protein c.
ES2058479T3 (es) Compuestos peptidicos.
ES2099274T3 (es) Derivados de estreptolisina o.
NO893106D0 (no) Visse imidazo(4,5-b)pyridinderivater.
ATE59777T1 (de) Therapeutische zusammenstellungen auf basis von 3-alkoxyflavonen und derivate von 3-alkoxyflavonen.
DE3878988D1 (de) 1,2-di(4-isobutylphenyl)aethylen, dessen herstellung und verwendung als zwischenprodukt.
DE68903983D1 (de) 1,6-diazaspiro(4,4)nonan-2,7-dion-derivate.
FI950779A0 (fi) Homepromoottorit, jotka ovat aktiivisia glukoosin läsnäollessa
ITRM930343A0 (it) Proteine ricombinanti, vettori per l'espressione e loro usi.

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 0575054

Country of ref document: EP

REN Ceased due to non-payment of the annual fee